Pulmonary Aspergillosis

 

 Permissions and Reprints

ABSTRACT

As the population of patients with prolonged neutropenia, those receiving hematopoietic stem cell transplantation or lung transplantation, or those with human immunodeficiency virus or acquired immunodeficiency syndrome continues to increase, the rising incidence of pulmonary aspergillosis is unlikely to diminish. Aspergillus species are ubiquitous in nature, have no geographic predilection, and the spectrum of disease they cause is myriad, ranging from noninvasive disease with colonization to disseminated disease with an associated high mortality rate. The extent of disease is thus largely responsible for both the choice and the duration of antifungal therapy. Recent years have seen an expansion of antifungal agents, with efficacy against Aspergillus requiring an understanding of the full spectrum of disease for them to be used appropriately. Diagnosis is often difficult because existing tests lack desired sensitivity or specificity.

REFERENCES

• 1 Walsh T J, Anaissie E J, Denning D W, Herbrecht R et al.. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (IDSA).  Clin Infect Dis. 2008;  46(3) 327-360
  CrossrefPubMedGoogle Scholar
• 2 Patterson T F, Kirkpatrick W R, White M et al.. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.  Medicine. 2000;  79 250-260
  CrossrefPubMedGoogle Scholar
• 3 Anaissie E J, Stratton S L, Dignani M C et al.. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study.  Clin Infect Dis. 2002;  34 780-789
  CrossrefPubMedGoogle Scholar
• 4 Warris A, Voss A, Abrahamsen T G, Verweij P E. Contamination of hospital water with Aspergillus fumigatus and other molds.  Clin Infect Dis. 2002;  34 1159-1160
  CrossrefPubMedGoogle Scholar
• 5 Torres H A, Rivero G A, Lewis R E et al.. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus .  Diagn Microbiol Infect Dis. 2003;  46 25-28
  CrossrefPubMedGoogle Scholar
• 6 Patterson J E, Peters J, Calhoon J H et al.. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.  Transpl Infect Dis. 2000;  2 22-28
  CrossrefPubMedGoogle Scholar
• 7 Paterson D L, Singh N. Invasive aspergillosis in transplant recipients.  Medicine. 1999;  78 123-138
  CrossrefPubMedGoogle Scholar
• 8 Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy.  N Engl J Med. 2001;  344 1099-1100
  CrossrefPubMedGoogle Scholar
• 9 Cohen M S, Isturiz R E, Malech H L et al.. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi.  Am J Med. 1981;  71 59-66
  CrossrefPubMedGoogle Scholar
• 10 Denning D W. Aspergillosis in “nonimmunocompromised” critically ill patients.  Am J Respir Crit Care Med. 2004;  170 580-581
  CrossrefPubMedGoogle Scholar
• 11 Gerson S L, Talbot G H, Hurwitz S et al.. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.  Ann Intern Med. 1984;  100 345-351
  PubMedGoogle Scholar
• 12 Wald A, Leisenring W, van Burik J A, Bowden R A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.  J Infect Dis. 1997;  175 1459-1466
  CrossrefPubMedGoogle Scholar
• 13 Denning D W. Invasive aspergillosis.  Clin Infect Dis. 1998;  26 781-803
  CrossrefPubMedGoogle Scholar
• 14 Greene R. The radiological spectrum of pulmonary aspergillosis.  Med Mycol. 2005;  43(Suppl 1) S147-S154
  CrossrefPubMedGoogle Scholar
• 15 Denning D W, Follansbee S E, Scolaro M et al.. Pulmonary aspergillosis in the acquired immunodeficiency syndrome.  N Engl J Med. 1991;  324 654-662
  CrossrefPubMedGoogle Scholar
• 16 Kramer M R, Denning D W, Marshall S E et al.. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis.  Am Rev Respir Dis. 1991;  144(3 Pt 1) 552-556
  CrossrefPubMedGoogle Scholar
• 17 Binder R E, Faling L J, Pugatch R D, Mahasaen C, Snider G L. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity.  Medicine. 1982;  61 109-124
  CrossrefPubMedGoogle Scholar
• 18 Gefter W B, Weingrad T R, Epstein D M, Ochs R H, Miller W T. “Semi-invasive” pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung.  Radiology. 1981;  140 313-321
  PubMedGoogle Scholar
• 19 Hope W W, Walsh T J, Denning D W. The invasive and saprophytic syndromes due to Aspergillus spp.  Med Mycol. 2005;  43(Suppl 1) S207-S238
  CrossrefPubMedGoogle Scholar
• 20 Denning D W, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.  Clin Infect Dis. 2003;  37(Suppl 3) S265-S280
  CrossrefPubMedGoogle Scholar
• 21 Lin S J, Schranz J, Teutsch S M. Aspergillosis case-fatality rate: systematic review of the literature.  Clin Infect Dis. 2001;  32 358-366
  CrossrefPubMedGoogle Scholar
• 22 Greenberger P A. Allergic bronchopulmonary aspergillosis.  J Allergy Clin Immunol. 2002;  110 685-692
  CrossrefPubMedGoogle Scholar
• 23 Stevens D A, Schwartz H J, Lee J Y et al.. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.  N Engl J Med. 2000;  342 756-762
  CrossrefPubMedGoogle Scholar
• 24 Munoz P, Alcala L, Sanchez Conde M et al.. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis.  Transplantation. 2003;  75 326-329
  CrossrefPubMedGoogle Scholar
• 25 Horvath J A, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis.  Am J Med. 1996;  100 171-178
  CrossrefPubMedGoogle Scholar
• 26 Herbrecht R, Letscher-Bru V, Oprea C et al.. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.  J Clin Oncol. 2002;  20 1898-1906
  CrossrefPubMedGoogle Scholar
• 27 Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.  Blood. 2001;  97 1604-1610
  CrossrefPubMedGoogle Scholar
• 28 Verweij P E, Mennink-Kersten M A. Issues with galactomannan testing.  Med Mycol. 2006;  44(Suppl) 179-183
  CrossrefPubMedGoogle Scholar
• 29 Odabasi Z, Mattiuzzi G, Estey E et al.. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.  Clin Infect Dis. 2004;  39 199-205
  CrossrefPubMedGoogle Scholar
• 30 Donnelly J P. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go.  Clin Infect Dis. 2006;  42 487-489
  CrossrefPubMedGoogle Scholar
• 31 Bates D W, Su L, Yu D T et al.. Mortality and costs of acute renal failure associated with amphotericin B therapy.  Clin Infect Dis. 2001;  32 686-693
  PubMedGoogle Scholar
• 32 Cornely O A, Maertens J, Bresnik M et al.. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).  Clin Infect Dis. 2007;  44 1289-1297
  CrossrefPubMedGoogle Scholar
• 33 Eiden C, Peyriere H, Cociglio M et al.. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.  Ann Pharmacother. 2007;  41 755-763
  CrossrefPubMedGoogle Scholar
• 34 Steinbach W J, Stevens D A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.  Clin Infect Dis. 2003;  37(Suppl 3) S157-S187
  CrossrefPubMedGoogle Scholar
• 35 Herbrecht R, Denning D W, Patterson T F et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.  N Engl J Med. 2002;  347 408-415
  CrossrefPubMedGoogle Scholar
• 36 De Beule K, Van Gestel J. Pharmacology of itraconazole.  Drugs. 2001;  61(Suppl 1) 27-37
  PubMedGoogle Scholar
• 37 Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.  Br J Clin Pharmacol. 2004;  57 218-222
  CrossrefPubMedGoogle Scholar
• 38 Ullmann A J, Lipton J H, Vesole D H et al.. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.  N Engl J Med. 2007;  356 335-347
  CrossrefPubMedGoogle Scholar
• 39 Cornely O A, Maertens J, Winston D J et al.. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.  N Engl J Med. 2007;  356 348-359
  CrossrefPubMedGoogle Scholar
• 40 Bennett J E. Echinocandins for candidemia in adults without neutropenia.  N Engl J Med. 2006;  355 1154-1159
  CrossrefPubMedGoogle Scholar
• 41 Marr K A, Boeckh M, Carter R A, Kim H W, Corey L. Combination antifungal therapy for invasive aspergillosis.  Clin Infect Dis. 2004;  39 797-802
  CrossrefPubMedGoogle Scholar

Thomas F PattersonM.D. 

Department of Medicine, Division of Infectious Diseases

UTHSCSA, 7703 Floyd Curl Dr., San Antonio, TX 78229

Email: patterson@uthscsa.edu